Clinical pharmacokinetics and tolerability of alpidem in healthy subjects given increasing single doses

[1]  G. Bianchetti,et al.  Plasma protein binding of alpidem in healthy volunteers, in neonates and in liver or renal insufficiency , 2004, European Journal of Clinical Pharmacology.

[2]  K. Lloyd,et al.  Selectivity for Omega-Receptor Subtypes as a Strategy for the Development of Anxiolytic Drugs , 1990, Pharmacopsychiatry.

[3]  P. Morselli,et al.  Clinical studies with the new anxiolytic alpidem in anxious patients: An overview of the European experiences , 1988, Pharmacology Biochemistry and Behavior.

[4]  M. Lader.  Clinical pharmacology of non-benzodiazepine anxiolytics , 1988, Pharmacology, Biochemistry and Behavior.

[5]  S. Z. Langer,et al.  Imidazopyridines as a tool for the characterization of benzodiazepine receptors: A proposal for a pharmacological classification as omega receptor subtypes , 1988, Pharmacology Biochemistry and Behavior.

[6]  J. Feighner,et al.  Pilot study of alpidem, a novel imidazopyridine compound, in anxiety. , 1988, Psychopharmacology bulletin.

[7]  H. Curran,et al.  The effects of single doses of alpidem and lorazepam on memory and psychomotor performance in normal humans , 1987, Journal of psychopharmacology.

[8]  V. Ascalone,et al.  Determination of alpidem and its metabolites in human plasma by high-performance liquid chromatography and fluorimetric detection. , 1987, Journal of chromatography.

[9]  B. Saletu,et al.  Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry. , 1986, International clinical psychopharmacology.

[10]  B. Saletu,et al.  Sleep laboratory study of a new antianxiety drug, alpidem: short-term trial , 1986 .

[11]  S. Snyder,et al.  Two distinct solubilized benzodiazepine receptors: differential modulation by ions , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.